Mao Jiakai, Tian Yu, Luo Nan
Department of Hepatobiliary and Pancreatic Surgery, Department of General Surgery, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China.
Department of Vascular Surgery, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China.
Heliyon. 2024 Mar 14;10(7):e27301. doi: 10.1016/j.heliyon.2024.e27301. eCollection 2024 Apr 15.
Less than 10% of people who have pancreatic ductal adenocarcinoma (PDAC) will survive the malignancy for five years. The ion channel genes-related biomarker and predictive model were needed for exploitation.
Differentially expressed ion channel genes (DEICGs) were detected in PDAC patients. GO and KEGG enrichment analysis was conducted on DEICGs. The prognostic genes were found using Cox regression analysis. After that, a risk model was created and examined. A nomogram was created based on independent predictive analysis. The molecular functions of two risk groups were explored. Immune checkpoint molecule expression was compared in two risk groups. We evaluated the possible cancer immunotherapy response in two risk groups using the TIDE method. We further examined how TRPV2 functions in PDAC as a potent oncogene and regulates the activity of macrophages by in vitro validation, including CCK8, EdU, and Transwell assays.
A total of twenty-four DEICGs were found. Next, we discovered that two DEICGs (TRPV2 and GJB3) were connected to PDAC patients' overall survival (OS). The risk model was created and validated, and a nomogram was used to forecast the overall survival of PDAC patients. The high-risk group considerably accumulated oncogenic pathways. Furthermore, we discovered a correlation between the expression of critical immunological checkpoints and the risk score. Furthermore, patients in the high-risk category had a lower chance of benefiting from immune therapy. The HPA database confirmed that TRPV2 is expressed as a protein. Lastly, TRPV2 controls macrophage activity and acts as a potent oncogene in PDAC.
Altogether, this study suggested that two ion channel genes, TRPV2 and GJB3, were potential biomarkers for the prognosis of PDAC and immunotherapy targets, and the research will be crucial for creating novel PDAC treatment targets and predictive molecular indicators.
胰腺导管腺癌(PDAC)患者中,不到10%能存活5年。需要开发与离子通道基因相关的生物标志物和预测模型。
在PDAC患者中检测差异表达的离子通道基因(DEICGs)。对DEICGs进行GO和KEGG富集分析。使用Cox回归分析找出预后基因。之后,创建并检验风险模型。基于独立预测分析创建列线图。探索两个风险组的分子功能。比较两个风险组中免疫检查点分子的表达。我们使用TIDE方法评估两个风险组中可能的癌症免疫治疗反应。我们通过体外验证,包括CCK8、EdU和Transwell试验,进一步研究TRPV2在PDAC中作为一种有效的癌基因的功能以及调节巨噬细胞活性的机制。
共发现24个DEICGs。接下来,我们发现两个DEICGs(TRPV2和GJB3)与PDAC患者的总生存期(OS)相关。创建并验证了风险模型,使用列线图预测PDAC患者的总生存期。高风险组显著积累致癌途径。此外,我们发现关键免疫检查点的表达与风险评分之间存在相关性。此外,高风险组患者从免疫治疗中获益的机会较低。HPA数据库证实TRPV2以蛋白质形式表达。最后,TRPV2在PDAC中控制巨噬细胞活性并作为一种有效的癌基因发挥作用。
总之,本研究表明TRPV2和GJB3这两个离子通道基因是PDAC预后的潜在生物标志物和免疫治疗靶点,该研究对于创建新的PDAC治疗靶点和预测分子指标至关重要。